The stock's fall snapped a five-day winning streak.

Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Image of Cathie Wood via Wikimedia Commons. In a market dominated by headlines about artificial intelligence (AI), cloud ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made million-dollar bets in the artificial intelligence (AI) and ...

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $106.00. The company’s shares closed today at $96.94. Eleva ...

According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why.

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of Illumina Inc. ILMN slid 1.84% to $97.44 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,263.26 and ...

Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.

Illumina (ILMN) stock downgraded to Sell while Charles River (CRL) stock and Hologic (HOLX) stock were upgraded to buy at Citi. Read more here.